180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Up 67.2% in March

180 Life Sciences Corp. (NASDAQ:ATNF) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 56,000 shares, an increase of 67.2% from the February 28th total of 33,500 shares. Currently, 4.1% of the company’s shares are short sold. Based on an average daily volume of 392,200 shares, the short-interest ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 180 Life Sciences in a research note on Saturday, March 22nd.

180 Life Sciences Stock Performance

Shares of ATNF stock opened at $1.00 on Monday. The company’s 50-day simple moving average is $1.27 and its two-hundred day simple moving average is $1.98. 180 Life Sciences has a one year low of $0.98 and a one year high of $17.75.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in 180 Life Sciences stock. Anson Funds Management LP purchased a new position in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 225,271 shares of the company’s stock, valued at approximately $410,000. Anson Funds Management LP owned approximately 7.08% of 180 Life Sciences at the end of the most recent quarter. Institutional investors own 4.07% of the company’s stock.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.